Pulse Explorer nav.journalClub Débats Tendances Chercheurs

Join discussions, follow papers, and never miss your next session.

Download on theApp Store

Accueil Explorer nav.journalClub Tendances

⌘+K

CHEK2, breast cancer, and the understanding of clinical utility | Synapse

June 7, 2010

View Full Paper

CHEK2, breast cancer, and the understanding of clinical utility

Key Points

Key points are not available for this paper at this time.

Abstract

Robson M. CHEK2 , breast cancer, and the understanding of clinical utility.

Demander à l'IA

Like

Bookmark

Share

View Full Paper

Cite This Study

Mark E. Robson (Mon,) studied this question.

synapsesocial.com/papers/6a1b65afdb618aee6aabd773 https://doi.org/https://doi.org/10.1111/j.1399-0004.2010.01444.x

Demander à l'IA

Like

Bookmark

Share

View Full Paper

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1The Evaluation of Genomic Applications in Practice and Prevention (EGAPP) initiative: methods of the EGAPP Working Group2009 · 675 citations
2Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from <i>BRCA</i> Mutation Carriers2009 · 3,636 citations
3Breast cancer risks in individuals testing negative for a known family mutation in BRCA1 or BRCA22009 · 49 citations
4Heterozygous Germ Line <i>hCHK2</i> Mutations in Li-Fraumeni Syndrome1999 · 902 citations
5Risk for contralateral breast cancer among carriers of the CHEK2*1100delC mutation in the WECARE Study2008 · 49 citations